9 Ways Perimenopause Alters Seizure Frequency and Medication Effectiveness in Women With Epilepsy
If you have epilepsy and suddenly felt like your seizure control was slipping in your 40s — and your neurologist kept adjusting your medication without anyone mentioning hormones — you are not imagining things, and you are not alone. The connection between perimenopause and seizure threshold is real, it is measurable, and it deserves to be part of every conversation happening in that neurology office.
Learn more about Rose →Progesterone Acts as a Natural Anticonvulsant — and Perimenopause Takes It Away
Progesterone is metabolized in the brain into allopregnanolone, a neurosteroid that enhances GABA-A receptor activity — the same inhibitory pathway targeted by many anticonvulsant drugs. As progesterone levels decline and become erratic during perimenopause, this natural brake on neuronal excitability weakens measurably. Women with epilepsy who had relatively stable seizure control during their reproductive years may find that stability eroding without any change in their medication, simply because their endogenous anticonvulsant supply has dried up.
Catamenial Epilepsy Patterns Can Worsen and Then Become Unrecognizable
Catamenial epilepsy — seizures that cluster around specific phases of the menstrual cycle — affects roughly one-third of women with epilepsy during their reproductive years, and it is driven by the ratio of estrogen to progesterone. In perimenopause, cycles become irregular and anovulatory cycles become common, meaning progesterone is sometimes absent entirely in a given month while estrogen fluctuates wildly. The predictable pattern a woman may have used to plan her life around can dissolve into unpredictable, cycle-independent seizure clusters that are harder to anticipate or explain.
Estrogen Has Proconvulsant Properties That Go Unchecked When Progesterone Falls
Estrogen is not simply the counterpart to progesterone — it actually has excitatory effects on neuronal tissue and has been shown to lower seizure threshold in animal and human studies. During the hormonal chaos of perimenopause, estrogen levels do not simply drop; they surge unpredictably before declining, and without sufficient progesterone to balance those surges, women with epilepsy can experience windows of heightened seizure vulnerability. This estrogen-dominance pattern, familiar to many perimenopausal women for other reasons, has specific neurological consequences that are rarely discussed in clinical practice.
Sleep Disruption Lowers Seizure Threshold Independently of Hormones
Sleep deprivation is one of the most well-established triggers for seizures across all epilepsy types, and perimenopause is notorious for fragmenting sleep through night sweats, insomnia, and disrupted sleep architecture. For a woman with epilepsy, the compounding effect is significant: hormonal changes are already shifting her seizure threshold downward, and chronic poor sleep pushes it further in the same direction. This means that even if hormone levels on a given day look relatively stable, a run of bad nights can be enough to tip the balance toward breakthrough seizures.
Enzyme-Inducing AEDs Can Accelerate Hormonal Decline
Several commonly prescribed antiepileptic drugs — including carbamazepine, phenytoin, phenobarbital, and oxcarbazepine — induce cytochrome P450 liver enzymes that accelerate the metabolism of sex hormones, effectively lowering circulating estrogen and progesterone levels faster than they would otherwise decline. For a perimenopausal woman with epilepsy, this creates a compounding problem: her hormones are already falling, and her seizure medication may be actively speeding that process up. This interaction is clinically relevant but rarely flagged when these medications are prescribed or reviewed.
Hormone Therapy Decisions Become Significantly More Complex With Epilepsy
Menopausal hormone therapy (MHT) is a reasonable and evidence-supported option for managing perimenopausal symptoms, but for women with epilepsy, the decision involves neurological considerations that most gynecologists are not trained to weigh. Estrogen-only or estrogen-dominant formulations may worsen seizure control, while formulations that include progesterone — particularly natural micronized progesterone — may actually offer some protective benefit due to its allopregnanolone conversion. Getting this right requires a conversation between neurology and gynecology that, in most healthcare systems, simply does not happen unless the patient forces it.
AED Blood Levels Can Shift as Body Composition and Metabolism Change
Perimenopause is associated with changes in body fat distribution, liver enzyme activity, and kidney function — all of which affect how antiepileptic drugs are absorbed, distributed, and cleared from the body. A dose that maintained therapeutic blood levels for years may become subtly insufficient or, in some cases, accumulate to mildly toxic levels, without any change in the prescription. Women with epilepsy in perimenopause should ideally have AED serum levels monitored more frequently during this transition, but this is not standard practice in most neurology settings.
Mood Changes and Anxiety in Perimenopause Can Mimic or Mask Seizure Activity
Perimenopausal women commonly experience anxiety, mood swings, depersonalization, and cognitive disruption — symptoms that can overlap significantly with the postictal state, focal aware seizures, or absence seizures, making self-monitoring harder and symptom reporting to neurologists less accurate. Conversely, women and their doctors may attribute genuine seizure activity to hormonal mood changes and delay appropriate medication review. This diagnostic blurring is particularly dangerous because it can allow a meaningful increase in seizure frequency to go unaddressed for months.
The Absence of a Shared Care Protocol Means Women Must Become Their Own Coordinators
There is currently no widely adopted clinical guideline requiring neurologists and menopause specialists to co-manage women with epilepsy during perimenopause, despite the clear biological interactions between hormone fluctuation and seizure threshold. In practice, this means a woman's neurologist adjusts her AED in response to breakthrough seizures without knowing her hormonal picture, while her gynecologist manages hot flushes without knowing her seizure history or current medications. Until formal care coordination pathways exist, women in this situation are best served by proactively sharing records between their care teams and specifically asking each provider whether hormonal changes have been factored into their treatment decisions.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.